CSBI Releases the 2023 Life Sciences Workforce Trends Report at BIO International Convention

BOSTON, MASS., U.S.A., June 7, 2023/ EINPresswire.com / —  The Coalition of State Bioscience Institutes  (CSBI) releases the 2023 Life Sciences Workforce Trends Report with TEConomy Partners this week at the  2023 BIO International Convention  in Boston. The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.

Cover of CSBI 2023 Life Sciences Workforce Trends Report

This sixth edition of the Workforce Trends report looks at trends that have gripped the industry in recent years, including: the implications of technology investments and deployment for high-demand occupations and skills; the industry’s continued and maturing emphasis on advancing diversity, equity, and inclusion (DEI); the solidifying of remote and hybrid work arrangements; and the need to evolve and deepen industry-academic partnerships as a cornerstone of targeted talent solutions to meet the industry’s outsized demand.

“The CSBI TEConomy report continues to stay abreast of our booming industry’s evolving talent needs,” said Rachel King, President & CEO of the Biotechnology Innovation Organization. “Its timely data, collected with the help of so many of our state and territorial trade associations and institutes, positions us to collectively work to develop a diverse workforce that will lead innovative discoveries and solutions across the globe.”

As in 2021, this year’s report has been produced in collaboration with and with support from InnovATEBIO, a National Advanced Technology Education Center supporting biotechnology education in community colleges supported by the National Science Foundation. The report will be featured at InnovATEBIO’s upcoming National Summit in June at the National Academy of Sciences: Envisioning the Next Bioscience Workforce: A Summit on Industry Trends and Needs.

“The National Science Foundation is pleased to once again support this important collaboration for addressing the industry’s need for highly skilled technical talent, an area where demand continues to critically outpace supply,” stated Dr. Celeste Carter, Lead Program Director, NSF Advanced Technological Education Program. “Working together, InnovATEBIO and CSBI are helping to facilitate the industry-academic-government collaborations that will drive targeted workforce solutions for the U.S. life sciences industry.”

As the country and globe begin to climb out of COVID and to wrestle with continued economic uncertainty, regulation, and more, the life science industry continues to surge ahead, today employing 2.2 million people and expanding its labor force by a net 169,000 workers since 2020. This strong growth in hiring has played out as the overall economy has rebounded and ramped up, leading to intense competition for talent and subsequent impacts on wage growth, recruitment, retention and baseline hiring criteria.

“Mid-way into 2023, it is even more clear to us that we need to bring together the thought leadership, resources and will of multiple stakeholders if we are going to help the U.S. life science industry develop and groom the talent needed to keep up with its accelerated workforce and economic engine,” said Liisa Bozinovic, CSBI Chair and Executive Director of the Oregon Bioscience Association. “CSBI will be working to facilitate and deepen several ‘ecosystem’ partnerships and resources over the next year to address these common talent challenges.”

Download key findings and full report at  www.csbioinstitutes.org.

About the Coalition for State Biotech Institutes (CSBI)
 The Coalition for State Biotech Institutes is dedicated to ensuring America’s leadership in bioscience innovation by delivering industry-led life science education and workforce development programs through a nationally coordinated effort. Programs are uniquely positioned for life science industry to deliver, replicable in states across the U.S., extensible to other STEM industry sectors and are fully aligned with emerging K-12 Common Core Learning Standards. Learn more at  www.csbioinstitutes.org.

About TEConomy Partners, LLC
 TEConomy Partners, LLC is a global leader in research, analysis and strategy for innovation-driven economic development. Today we’re helping nations, states, regions, universities and industries blueprint their future and translate knowledge into prosperity. The principals of TEConomy Partners include the authors of the biennial TEConomy/BIO State Bioscience Development reports, published since 2004. For further information, please visit  www.teconomypartners.com.

BIO Statement on the Section 232 Pharmaceutical Proclamation

April 4, 2026
April 2, 2026- WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) , released the following statement on Section 232 Pharmaceutical Proclamation. “A thriving American biotechnology ecosystem is essential to growing the U.S. economy, strengthening national security, and improving the health and well‑being of everyday Americans. While we appreciate the Administration’s recognition of the need for tariff exemptions for certain critical biotech products, the reality is that any tariffs on America’s medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments - all while doing nothing to enhance our national security. “U.S. biotech companies have been eager to expand investments here at home, but tariffs, along with an uncertain policy environment and efforts to force “most‑favored nation” schemes, work directly against that goal. The risks are especially acute for small and mid‑size biotech companies, which develop more than half of all FDA‑approved medicines yet often lack the capital to build dedicated manufacturing facilities as they weather an industry defined by high costs, long development timelines, and significant risk. “The fact is: tariffs divert scarce resources away from research and development, weaken American biotech against China’s rising industry, and ultimately, harm health and economic wellbeing of Americans. “We stand ready to work with the Administration on a long‑term strategy that encourages biotechnology investment, reduces the time, cost, and uncertainty of developing new medicines, expands U.S. biomanufacturing capacity, and ensures American innovation is fairly valued overseas. Tariffs and MFN are not the answer." Source - https://www.bio.org/press-release/bio-statement-section-232-pharmaceutical-proclamation

Georgia Life Sciences Announces 2026 Georgia BioGENEius Challenge Winner

April 1, 2026
Atlanta, GA (April 1, 2026) – Georgia Life Sciences (GLS) is proud to announce that Saisurya Lakkimsetti, a junior at Lakeside High School in Columbia County, has been named the winner of the 2026 Georgia BioGENEius Challenge. The Georgia BioGENEius Challenge took place, as part of the statewide Georgia Science and Engineering Fair (GSEF) at the Classic Center in Athens, Georgia. Forty-seven students from across Georgia competed for this year’s title and cash prize. Jaehyeon Lee, an 11th-grade student from Walton High School, was named runner-up in this year’s competition. The Georgia BioGENEius Challenge recognizes outstanding high school students who are conducting innovative biotechnology research with real-world applications. This year’s top projects, presented in the Global Healthcare Challenge track, demonstrated exceptional scientific rigor and forward-thinking potential in addressing critical healthcare challenges. Saisurya’s research focuses on identifying potential inhibitors for Endocan, a protein known to play a role in glioblastoma tumor growth. Using advanced computational modeling techniques—including AlphaFold and molecular docking tools—she screened thousands of small molecules to identify compounds that may block tumor-promoting signaling pathways. Her work identified several promising candidates that could serve as a foundation for future drug development targeting glioblastoma. Jaehyeon’s project investigates how varying glucose concentrations affect regeneration in planaria, modeling impaired wound healing in diabetic conditions. By testing graded glucose environments and measuring regeneration indicators such as growth and differentiation, Jaehyeon demonstrated that lower glucose levels enhance regeneration while higher levels inhibit healing. The study establishes a model to better understand hyperglycemia’s impact on diabetic wound healing. “The work by these students is a powerful example of the innovation and determination we see in Georgia’s next generation of life sciences leaders,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences. “The BioGENEius Challenge is critical because it provides students with a platform to apply cutting-edge science to real-world problems, while also strengthening the future workforce that will drive breakthroughs in healthcare, biotechnology, and beyond.” The Georgia BioGENEius Challenge is part of Georgia Life Sciences’ broader commitment to advancing workforce development and fostering innovation across the state’s rapidly growing life sciences ecosystem. Judging the 2026 Georgia BioGENEius Challenge: Ian Biggs; Ralph Cordell, CDC; Alex Harvey, ViaMune; Jamie Graham, Smith Gambrell Russell; and Evan Scullin, LuminiSci.

Georgia Life Science's Feature in Very First Atlanta Edition of Inside Medicine

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
MORE POSTS